DA
Therapeutic Areas
SELLAS Life Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Galinpepimut-S (GPS) | Acute Myeloid Leukemia (AML) | Phase 2/3 |
| Nelipepimut-S (NPS) | HER2 Low-Expressing Breast Cancer | Phase 2b |
| SLS009 (GFH009) | Acute Myeloid Leukemia (AML) | Phase 1/2 |
Leadership Team at SELLAS Life Sciences
AM
Angelos M. Stergiou
President, Chief Executive Officer, and Chairman of the Board
DC
Dragan Cicic
Senior Vice President, Clinical Development
MC
Marina C. Simeonova
Chief Financial Officer
NJ
Nicholas J. Sarlis
Senior Vice President, Chief Medical Officer
RL
Robert L. Van Nostrand
Senior Vice Director, Corporate Development & Investor Relations
JG
Joseph G. Grosso
Director
BW
Barbara Wood
Director
SR
Stephen R. Biggar
Director
ER
Eric R. Bjerkholt
Director
ID
Igor D. Luzhin
Director